ziltivekimab novo nordisk：ZEUS
ZEUS
Thisstudyisconductedtoseeifziltivekimabreducestheriskofhavingcardiovascularevents(forexampleheartattackandstroke)inpeoplewith ...。其他文章還包含有：「Cardiovasculardisease」、「Ziltivekimab」、「R&Dpipeline」、「WhatisthecurrentvaluationofNovoNordisk'sZiltivekimab」、「NCT05021835」、「Ziltivekimab-NovoNordisk」、「Ziltivekimabreducedinflammatorybiomarkersassociated...」、「hermes」、「Ar...
查看更多 離開網站
Cardiovascular disease
https://www.novonordisk.com
Source: Ridker PM, et al., IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, ...
Ziltivekimab
https://en.wikipedia.org
Ziltivekimab is a fully human monoclonal antibody against interleukin 6. It is developed by Novo Nordisk to treat heart failure.
R&D pipeline
https://www.novonordisk.com
Explore our pipeline ; Ziltivekimab AMI. Acute Myocardial infarction (AMI) ; Icosema. Diabetes ; Oral Semaglutide 25 mg and 50 mg. Diabetes ; CagriSema in T2D.
What is the current valuation of Novo Nordisk's Ziltivekimab
https://www.pharmaceutical-tec
Ziltivekimab is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Systolic Heart Failure.
NCT05021835
https://clinicaltrials.gov
沒有這個頁面的資訊。
Ziltivekimab - Novo Nordisk
https://adisinsight.springer.c
Ziltivekimab is a fully human monoclonal antibody targeting interleukin-6 (IL-6), being developed by Novo Nordisk (formerly Corvidia ...
Ziltivekimab reduced inflammatory biomarkers associated ...
https://www.novonordisk-us.com
Ziltivekimab reduced inflammatory biomarkers associated with atherosclerosis in people with chronic kidney disease in phase 2 trial.
hermes
https://www.clinicaltrials.gov
沒有這個頁面的資訊。
A randomized, double-blind, placebo
https://pubmed.ncbi.nlm.nih.go
Ziltivekimab, a fully human monoclonal antibody targeting the interleukin-6 ligand, significantly reduced biomarkers of inflammation compared with placebo.